Rivaroxaban (with initial increased dosage) may be used as a stand-alone therapy in patients with venous thrombo-embolism. The development of new anticoagulant drugs opened several options in the management of venous thrombo-embolism. The efficacy and safety of these new oral anticoagulants in specific population as elderly and those with renal impairment deserve future research. At that time, only rivaroxaban is licensed in France, in the treatment of deep venous thrombosis.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.lpm.2013.06.001 | DOI Listing |
Publication Analysis
Top Keywords
oral anticoagulants
8
venous thrombo-embolism
8
[new oral
4
anticoagulants treatment
4
venous
4
treatment venous
4
venous thromboembolism]
4
thromboembolism] rivaroxaban
4
rivaroxaban initial
4
initial increased
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!